Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG

SAN CARLOS, Calif.--(BUSINESS WIRE)-- #CDG--Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG

Click to view original post